Headspace and Ginger have completed their $3 billion combination to create Headspace Health, a new frontrunner in the rapidly growing digital mental health and wellbeing sectors.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh